Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung.

Slides:



Advertisements
Similar presentations
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Advertisements

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer:
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas  Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication 
Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR  Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,
EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy  Michele.
OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer
Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients  Camilla Maria T. Sagerup, MD, Milada.
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.
Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients  Satu Mäki-Nevala, MSc, Mikko Rönty, MD, Mike Morel, MBiolSci,
Estrogen Receptor (ER) and Epidermal Growth Factor Receptor (EGFR) as Targets for Dual Lung Cancer Therapy: Not Just a Case?  Monica Giovannini, MD, Carmen.
Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors  Su Jin Lee, MD, Jung-Il Lee,
The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer  Peter Goldstraw, MB, FRCS, John J. Crowley, PhD 
Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients  Carmelo Tibaldi, MD,
EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients  Jangchul Park, MD, Chiaki Kondo, MD, Junichi.
Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma  Tzu-Hsiu Tsai,
Pyrosequencing Analysis of EGFR and KRAS Mutations in EUS and EBUS-Derived Cytologic Samples of Adenocarcinomas of the Lung  Jos A. Stigt, MD, Nils A.
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer 
Epidermal Growth Factor Receptor, C-kit, and Her2/neu Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the 2004.
Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation  Lars Soraas, MSc, Justin Stebbing,
Clinical courses of patients.
Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature  Caicun Zhou, MD, PhD, Luan Di Yao, MD 
(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.
Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A
Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis  Bin-Chi Liao,
Erratum Journal of Thoracic Oncology
Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy.
Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q  Satoshi Watanabe, MD, PhD, Yuji Minegishi,
Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.
Ligands of Epidermal Growth Factor Receptor and the Insulin-Like Growth Factor Family as Serum Biomarkers for Response to Epidermal Growth Factor Receptor.
Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation  Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.
Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for.
Aglaya G. Iyevleva, MD, PhD  Journal of Thoracic Oncology 
XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding.
EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer  Allison Ackerman, MD, Michael A. Goldstein,
Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase.
EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey  Daniel Morgensztern, MD, Shean Huey Ng,
Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung.
Relationship between Response and Survival in More Than 50,000 Patients with Advanced Non-small Cell Lung Cancer Treated with Systemic Chemotherapy in.
Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors 
MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next- Generation Sequencing and Successfully Treated with a MET Inhibitor  Carrie.
Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer  Emily Castellanos, MD, Emily Feld, MD, Leora.
Rapid Detection of Hotspot Mutations in Epidermal Growth Factor Receptor by Polymerase Chain Reaction Facilitates the Management of Non-small Cell Lung.
Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View  Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,
Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer  Yoon Hee Choi, MD,
Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone?  Alvaro Leone, BSc.D 
Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P
Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer  Elena Bolzacchini, MD,
Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer  Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,
Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation  Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.
Epidemiology of Thymoma and Associated Malignancies
Two Rare Exon 21 EGFR Mutations in Patients Treated with Gefitinib
Hyun-Sung Lee, MD, PhD, Cynthia Y. Truong, BS, Bryan M. Burt, MD 
Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.
Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure  Joel P. Womack,
A Review of First-Line Treatment for Small-cell Lung Cancer
The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients  Gokoulakrichenane Loganadane, MD, Lizza Hendriks, MD, PhD, Cécile.
Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.
Ana Luque, MD, Edurne Arriola, MD, PhD  Journal of Thoracic Oncology 
Presentation transcript:

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database  Samuel Murray, PhD, Issa J. Dahabreh, Helena Linardou, MD, PhD, Menelaos Manoloukos, MSc, Dimitrios Bafaloukos, MD, Paris Kosmidis, MD  Journal of Thoracic Oncology  Volume 3, Issue 8, Pages 832-839 (August 2008) DOI: 10.1097/JTO.0b013e31818071f3 Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Trial flow of database generation and data extraction. Journal of Thoracic Oncology 2008 3, 832-839DOI: (10.1097/JTO.0b013e31818071f3) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Distribution of somatic EGFR mutations. A, per exon and B, according to type (entire population). Journal of Thoracic Oncology 2008 3, 832-839DOI: (10.1097/JTO.0b013e31818071f3) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Frequency of reported incidence of somatic mutations in EGFR. Incidence of somatic mutations that have been reported on 1, 2, 3, 4, and ≥5 separate occasions. Also the number (incidence) of mutations that have a cumulative frequency of ≥1% of the total number of mutations reported (n = 3305). Journal of Thoracic Oncology 2008 3, 832-839DOI: (10.1097/JTO.0b013e31818071f3) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Response rates for somatic mutations per exon, total population, and per mutational type (cumulative data of treated patients for which response data exists). Responses are characterized as CR + PR, stable disease (disease stabilization), PD, nonevaluable. Total represents the percentage of each response group per stratification out of 100%. Point mutations represent missense mutations and frameshift mutations, Dels-Ins are a combination of deletions, insertions, and deletional-insertions (according to Table 2). All = all mutations. Journal of Thoracic Oncology 2008 3, 832-839DOI: (10.1097/JTO.0b013e31818071f3) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions